Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:135-142
Published online before print July 7, 2003, doi: 10.1161/01.CIR.0000081659.72985.A8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/2/135    most recent
01.CIR.0000081659.72985.A8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallentin, L.
Right arrow Articles by Van de Werf, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallentin, L.
Right arrow Articles by Van de Werf, F.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Blood Thinners
*Emergency Medical Services
*Heart Attack
Hazardous Substances DB
*HEPARIN
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Fibrinolysis
Right arrow Heparin
Right arrow Acute myocardial infarction
Right arrow Acute Cerebral Hemorrhage

(Circulation. 2003;108:135.)
© 2003 American Heart Association, Inc.


Clinical Investigation and Reports

Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting

The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction

L. Wallentin, MD, PhD; P. Goldstein, MD, PhD; P.W. Armstrong, MD; C.B. Granger, MD; A.A.J. Adgey, MD; H.R. Arntz, MD, PhD; K. Bogaerts, MSc; T. Danays, MD; B. Lindahl, MD, PhD; M. Mäkijärvi, MD, PhD; F. Verheugt, MD, PhD; F. Van de Werf, MD, PhD

From the Department of Cardiology and Uppsala Clinical Research Centre, Uppsala, Sweden (L.W., B.L.); Samu de Lille, Lille, France (P.G.); Department of Cardiology, University of Alberta, Edmonton, Canada (P.W.A.); Division of Cardiology, Duke University Medical Center, Durham, NC (C.B.G.); Department of Cardiology, Royal Victoria Hospital, Belfast, Northern Ireland (A.A.J.A.); Department of Cardiopulmology, Benjamin Franklin Medical Center, Free University of Berlin, Germany (H.R.A.); Biostatistical Centre, University of Leuven, Belgium (K.B.); Boehringer-Ingelheim, Ingelheim am Rhein, Germany (T.D.); Department of Medicine, University Central Hospital, Helsinki, Finland (M.M.); University Medical Center, Nijmegen, the Netherlands (F.V.); and Department of Cardiology, University of Leuven, Leuven, Belgium (F.V.d.W.).

Correspondence to Lars Wallentin, MD, PhD, Professor of Cardiology, Head Uppsala Clinical Research Center, Uppsala Clinical Research Center, Uppsala University Hospital, SE 751 85 Uppsala, Sweden. E-mail Lars.Wallentin{at}ucr.uu.se

Background— The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital reperfusion and further improve clinical outcome in patients with ST-elevation myocardial infarction.

Methods and Results— In the prehospital setting, 1639 patients with ST-elevation myocardial infarction were randomly assigned to treatment with tenecteplase and either (1) intravenous bolus of 30 mg enoxaparin (ENOX) followed by 1 mg/kg subcutaneously BID for a maximum of 7 days or (2) weight-adjusted unfractionated heparin (UFH) for 48 hours. The median treatment delay was 115 minutes after symptom onset (53% within 2 hours). ENOX tended to reduce the composite of 30-day mortality or in-hospital reinfarction, or in-hospital refractory ischemia to 14.2% versus 17.4% for UFH (P=0.080), although there was no difference for this composite end point plus in-hospital intracranial hemorrhage or major bleeding (18.3% versus 20.3%, P=0.30). Correspondingly, there were reductions in in-hospital reinfarction (3.5% versus 5.8%, P=0.028) and refractory ischemia (4.4% versus 6.5%, P=0.067) but increases in total stroke (2.9% versus 1.3%, P=0.026) and intracranial hemorrhage (2.20% versus 0.97%, P=0.047). The increase in intracranial hemorrhage was seen in patients >75 years of age.

Conclusions— Prehospital fibrinolysis allows 53% of patients to receive reperfusion treatment within 2 hours after symptom onset. The combination of tenecteplase with ENOX reduces early ischemic events, but lower doses of ENOX need to be tested in elderly patients. At present, therefore, tenecteplase and UFH are recommended as the routine pharmacological reperfusion treatment in the prehospital setting.


Key Words: myocardial infarction • fibrinolysis • hemorrhage • heparin • reperfusion




This article has been cited by other articles:


Home page
Arch Intern MedHome page
D. J. Quinlan and J. W. Eikelboom
Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction
Arch Intern Med, June 22, 2009; 169(12): 1163 - 1164.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager
Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
Ann. Pharmacother., June 1, 2009; 43(6): 1064 - 1083.
[Abstract] [Full Text] [PDF]


Home page
Emerg. Med. J.Home page
N A Rajabali, R T Tsuyuki, S Sookram, S H Simpson, and R C Welsh
Evaluation of attitudes and perceptions of key clinical stakeholders regarding out-of-hospital diagnosis and treatment of ST elevation myocardial infarction patients using a region-wide survey
Emerg. Med. J., May 1, 2009; 26(5): 371 - 376.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
V Bongard, J Puel, D Savary, L Belle, S Charpentier, Y Cottin, L Soulat, M Elbaz, D Miljkovic, P. G Steg, et al.
Predictors of infarct artery patency after prehospital thrombolysis: the multicentre, prospective, observational OPTIMAL study
Heart, May 1, 2009; 95(10): 799 - 806.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Horne, C Weston, T Quinn, A Hicks, L Walker, R Chen, and J Birkhead
The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP)
Heart, April 1, 2009; 95(7): 559 - 563.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R D Lopes, K S Pieper, J R Horton, S M Al-Khatib, L K Newby, R H Mehta, F Van de Werf, P W Armstrong, K W Mahaffey, R A Harrington, et al.
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
Heart, July 1, 2008; 94(7): 867 - 873.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 708S - 775S.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
American College of Cardiology/American Heart Asso, Developed in Collaboration With the Canadian Cardi, Endorsed by the American Academy of Family Physici, 2007 Writing Group to Review New Evidence and Upda, E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, et al.
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
J. Am. Coll. Cardiol., January 15, 2008; 51(2): 210 - 247.
[Full Text] [PDF]


Home page
CirculationHome page
E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, J. S. Hochman, H. M. Krumholz, G. A. Lamas, C. J. Mullany, et al.
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee
Circulation, January 15, 2008; 117(2): 296 - 329.
[Full Text] [PDF]


Home page
Card Surg AdultHome page
I. George and M. C. Oz
Myocardial Revascularization after Acute Myocardial Infarction
Card. Surg. Adult, January 1, 2008; 3(2008): 669 - 696.
[Full Text]


Home page
HeartHome page
C. Brasselet, S. Tassan, P. Nazeyrollas, M. Hamon, and D. Metz
Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI Trial
Heart, December 1, 2007; 93(12): 1556 - 1561.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. E. Boden, K. Eagle, and C. B. Granger
Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options
J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
K. A.A. Fox, J.-P. Bassand, S. R. Mehta, L. Wallentin, P. Theroux, L. S. Piegas, V. Valentin, T. Moccetti, S. Chrolavicius, R. Afzal, et al.
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non ST-Segment Elevation Acute Coronary Syndromes
Ann Intern Med, September 4, 2007; 147(5): 304 - 310.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. A. Murphy, C. M. Gibson, D. A. Morrow, F. Van de Werf, I. B. Menown, S. G. Goodman, K. W. Mahaffey, M. Cohen, C. H. McCabe, E. M. Antman, et al.
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
Eur. Heart J., September 1, 2007; 28(17): 2077 - 2086.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. P. Alexander, L. K. Newby, P. W. Armstrong, C. P. Cannon, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al.
Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Circulation, May 15, 2007; 115(19): 2570 - 2589.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
H. D. White, E. Braunwald, S. A. Murphy, A. J. Jacob, N. Gotcheva, L. Polonetsky, and E. M. Antman
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25
Eur. Heart J., May 1, 2007; 28(9): 1066 - 1071.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al.
Anticoagulants in heart disease: current status and perspectives
Eur. Heart J., April 10, 2007; (2007) ehl492v1.
[Full Text] [PDF]


Home page
CirculationHome page
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Circulation, December 19, 2006; 114(25): 2871 - 2891.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. W. Armstrong and WEST Steering Committee
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study
Eur. Heart J., July 1, 2006; 27(13): 1530 - 1538.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. W.A. Verheugt
Reperfusion Therapy Starts in the Ambulance
Circulation, May 23, 2006; 113(20): 2377 - 2379.
[Full Text] [PDF]


Home page
CMAJHome page
P. W. Armstrong, W.-C. Chang, L. Wallentin, P. Goldstein, C. B. Granger, K. Bogaerts, T. Danays, F. Van de Werf, and for the ASSENT-3 and ASSENT-3 PLUS Investigators
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
Can. Med. Assoc. J., May 9, 2006; 174(10): 1421 - 1426.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
A. L. Bailey and S. R. Steinhubl
Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.
Can. Med. Assoc. J., May 9, 2006; 174(10): 1431 - 1432.
[Full Text] [PDF]


Home page
NEJMHome page
E. M. Antman, D. A. Morrow, C. H. McCabe, S. A. Murphy, M. Ruda, Z. Sadowski, A. Budaj, J. L. Lopez-Sendon, S. Guneri, F. Jiang, et al.
Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction
N. Engl. J. Med., April 6, 2006; 354(14): 1477 - 1488.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. J. Gibbons and V. Fuster
Therapy for Patients with Acute Coronary Syndromes -- New Opportunities
N. Engl. J. Med., April 6, 2006; 354(14): 1524 - 1527.
[Full Text] [PDF]


Home page
Eur Heart JHome page
W.-C. Chang, P. Kaul, Y. Fu, C. M. Westerhout, C. B. Granger, K. W. Mahaffey, L. Wallentin, F. Van de Werf, P. W. Armstrong, and for the ASSENT-3 Investigators
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction
Eur. Heart J., February 2, 2006; 27(4): 419 - 426.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Meurin, J. Y. Tabet, H. Weber, N. Renaud, and A. B. Driss
Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement
Circulation, January 31, 2006; 113(4): 564 - 569.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
H. Bueno, M. Martinez-Selles, E. Perez-David, and R. Lopez-Palop
Mechanisms of death in elderly patients with acute myocardial infarction exposed to fibrinolytic therapy: reply
Eur. Heart J., January 2, 2006; 27(2): 246 - 247.
[Full Text] [PDF]


Home page
CirculationHome page
M. S. Sabatine, D. A. Morrow, G. Montalescot, M. Dellborg, J. L. Leiva-Pons, M. Keltai, S. A. Murphy, C. H. McCabe, C. M. Gibson, C. P. Cannon, et al.
Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial
Circulation, December 20, 2005; 112(25): 3846 - 3854.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Circulation, December 20, 2005; 112(25): 3855 - 3867.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Part 8: Stabilization of the Patient With Acute Coronary Syndromes
Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110.
[Full Text] [PDF]


Home page
HeartHome page
R C Welsh and P W Armstrong
It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarction
Heart, December 1, 2005; 91(12): 1524 - 1526.
[Full Text] [PDF]


Home page
CirculationHome page
Part 5: Acute Coronary Syndromes
Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72.
[Full Text] [PDF]


Home page
HeartHome page
R C Welsh, W Chang, P Goldstein, J Adgey, C B Granger, F W A Verheugt, L Wallentin, F Van de Werf, P W Armstrong, and on behalf of the ASSENT-3 PLUS Investigators
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial
Heart, November 1, 2005; 91(11): 1400 - 1406.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. W. Armstrong
Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction
Eur. Heart J., October 1, 2005; 26(19): 1937 - 1938.
[Full Text] [PDF]


Home page
Eur Heart JHome page
C. J. Terkelsen, J. F. Lassen, B. L. Norgaard, J. C. Gerdes, S. H. Poulsen, K. Bendix, J. P. Ankersen, L. B.-H. Gotzsche, F. K. Romer, T. T. Nielsen, et al.
Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital diagnosis and direct referral to primary percutanous coronary intervention
Eur. Heart J., April 2, 2005; 26(8): 770 - 777.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. S Kalus and L. R Moser
Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction
Ann. Pharmacother., March 1, 2005; 39(3): 481 - 491.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. H. Mehta, C. B. Granger, K. P. Alexander, E. Bossone, H. D. White, and M. H. Sketch Jr
Reperfusion strategies for acute myocardial infarction in the elderly: Benefits and risks
J. Am. Coll. Cardiol., February 15, 2005; 45(4): 471 - 478.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Machecourt, E. Bonnefoy, G. Vanzetto, P. Motreff, S. Marliere, A. Leizorovicz, B. Allenet, J. M. Lacroute, J. Cassagnes, and P. Touboul
Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: The Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study
J. Am. Coll. Cardiol., February 15, 2005; 45(4): 515 - 524.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
The CREATE Trial Group Investigators*
Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
JAMA, January 26, 2005; 293(4): 427 - 435.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
B. S. Wiggins and S. Spinler
Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes
Journal of Pharmacy Practice, October 1, 2004; 17(5): 347 - 369.
[Abstract] [PDF]


Home page
ChestHome page
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 549S - 575S.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. M. Antman and F. Van de Werf
Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction
Circulation, June 1, 2004; 109(21): 2480 - 2486.
[Full Text] [PDF]


Home page
JRSMHome page
M. Kroese, D. Kanka, P. Weissberg, B. Arch, and J. Scott
Prehospital thrombolysis--calculated health benefit for catchment population of one hospital
J R Soc Med, May 1, 2004; 97(5): 230 - 234.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
P. W. Armstrong and R. C. Welsh
Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit
Can. Med. Assoc. J., October 28, 2003; 169(9): 925 - 927.
[Full Text]


Home page
Eur Heart JHome page
F. W.A. Verheugt
Combining glycoprotein blockers with fibrinolysis: a bold stroke?
Eur. Heart J., October 2, 2003; 24(20): 1801 - 1803.
[Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Prehospital Thrombolysis with LMWH vs. UFH
Journal Watch Cardiology, September 19, 2003; 2003(919): 3 - 3.
[Full Text]


Home page
JWatch Emergency Med.Home page
Prehospital TNK Plus Enoxaparin Increases Risk for Intracranial Hemorrhage
Journal Watch Emergency Medicine, September 10, 2003; 2003(910): 2 - 2.
[Full Text]